Comparative Pharmacology
Head-to-head clinical analysis: PERCODAN DEMI versus Q GESIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PERCODAN DEMI versus Q GESIC.
PERCODAN-DEMI vs Q-GESIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Oxycodone is a full mu-opioid receptor agonist; aspirin inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis.
Q-GESIC is a centrally acting non-opioid analgesic; its exact mechanism is unknown but may involve inhibition of cyclooxygenase (COX) and modulation of descending serotonergic and noradrenergic pathways.
1 tablet (oxycodone 2.25 mg/aspirin 325 mg) orally every 6 hours as needed for pain; maximum 4 tablets in 24 hours.
1-2 tablets (325-650 mg acetaminophen and 5-10 mg hydrocodone) orally every 4-6 hours as needed for pain; maximum 8 tablets per day.
None Documented
None Documented
Oxycodone: 3-4 hours; salicylate (aspirin): 2-3 hours at low doses, 15-30 hours at high doses; terminal half-life clinically relevant for dosing interval (q4-6h).
Terminal elimination half-life is 2-4 hours; clinical context: requires dosing every 4-6 hours for sustained analgesia.
Renal: ~90% (oxycodone: ~60% as metabolites, ~10% unchanged; aspirin: ~80% as salicylates, ~10% unchanged). Biliary/fecal: minor.
Renal excretion of unchanged drug accounts for 60-70% of elimination; biliary/fecal excretion accounts for 20-30%; <5% metabolized via CYP enzymes.
Category C
Category C
Opioid Analgesic Combination
Opioid Analgesic Combination